[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.187.2. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 1964

Treatment of Experimental Ocular Toxoplasmosis

Author Affiliations

Bethesda, Md
United States Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Parasitic Diseases (Dr. Jacobs, Miss Melton), and National Institute of Neurological Diseases and Blindness, Ophthalmology Branch (Dr. Kaufman).; Present address: University of Florida Medical Center, Gainesville, Fla (Dr. Kaufman).

Arch Ophthalmol. 1964;71(1):111-118. doi:10.1001/archopht.1964.00970010127020
Abstract

The importance of Toxoplasma as the cause of a substantial percentage of cases of posterior uveitis has been indicated by histopathological, serological, and clinical studies (see Frenkel and Jacobs, 1958, for review). The value of this advance has been mainly the possibility for successful treatment of some uveitides which were previously managed, without much success, by nonspecific therapy. A presumptive diagnosis of ocular toxoplasmosis has allowed the use of anti-Toxoplasma drugs, with encouraging results in a number of cases.

The effectiveness of pyrimethamine in murine toxoplasmosis was first reported by Eyles and Coleman (1952) and by Summers (1953) working independently. Eyles and Coleman (1953) demonstrated synergism between pyrimethamine and sulfadiazine in experimental infections in mice. These drugs have been used either singly or in combination in various clinical studies of ocular toxoplasmosis (Ryan et al, 1954; Perkins et al, 1956; Jacobs et al, 1956; Burnham and Beuerman, 1956; Kaufman,

First Page Preview View Large
First page PDF preview
First page PDF preview
×